A Case of Lung Adenocarcinoma Which Developed Carcinomatous Meningitis During Gefitinib Treatment, Improving After Switching to Erlotinib

Watanabe, Yasutaka; Kudo, Fumiaki; Shiraishi, Mamoru; Miwa, Chihiro; Matsumoto, Kenji; Koyama, Shinichiro

doi:10.2482/haigan.53.114

Cited by 3 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following the initial screening process, which involved removing ineligible articles and supplementing with studies from authors’ files, a total of 128 publications were ultimately included in the meta-analysis ( Appendix B and Appendix C ). 106 of the publications were case reports [ [14] , [15] , [16] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] , [55] , [56] , [57] , [58] , [59] , [60] , [61] , [62] , [63] , [64] , [65] , [66] , [67] , [68] , [69] , [70] , [71] , [72] , [73] , [74] , [75] , [76] , [77] , [78] , [79] , [80] , [81] , [82] , [83] , [84] , [85] , [86] , [87] , [88] , [89] , [90] , [91] , [92] , [93] , [94] , [95] , [96] , [97] , [98] , …”

Section: Resultsmentioning

confidence: 99%

Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysis

Bian,

Lazaratos,

Maritan

et al. 2024

Heliyon

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysis

Bian,

Lazaratos,

Maritan

et al. 2024

Heliyon

View full text Add to dashboard Cite

Gefitinib

2013

Reactions Weekly

View full text Add to dashboard Cite

Lung Adenocarcinoma in a Patient with a Reduced Performance Status due to Carcinomatous Meningitis That Showed a Remarkable Response to Osimertinib: a Case Report

Murao

Mori

Kobayashi

et al. 2021

JJLC

View full text Add to dashboard Cite

━━ Background. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI), is a first-line drug for EGFR mutation-positive advanced non-small cell lung carcinoma in patients with a good Performance Status (PS). However, there are few reports of the administration of osimertinib as a first-line treatment for patients with a poor PS. We herein report a case in which osimertinib was effective as a first-line treatment for advanced lung adenocarcinoma with a decreased PS due to carcinomatous meningitis. Case. A 79-year-old man was diagnosed with right middle lobe lung adenocarcinoma (cT4N0M1b cStage IVA) with carcinomatous meningitis. The patient was positive for the EGFR L858R mutation. Cognitive decline and ataxia due to carcinomatous meningitis were observed, and the patient had a PS of 3, which is classified as poor. However, the administration of osimertinib was started in consideration of the efficacy of the medicine for central nervous system lesions. After administration, the primary lesion shrank rapidly, and the patientʼs cognitive and motor functions improved. Conclusion.Osimertinib may a treatment option in first-line treatment of EGFR mutation-positive advanced nonsmall cell lung cancer in patients with a decreased PS due to paraneoplastic symptoms.

show abstract

A Case of Lung Adenocarcinoma Which Developed Carcinomatous Meningitis During Gefitinib Treatment, Improving After Switching to Erlotinib

Abstract: Background.Case. Conclusions.JJLC.

Cited by 3 publications

References 9 publications

Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysis

Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysis

Gefitinib

Lung Adenocarcinoma in a Patient with a Reduced Performance Status due to Carcinomatous Meningitis That Showed a Remarkable Response to Osimertinib: a Case Report

Contact Info

Product

Resources

About